About Insitro
Insitro is a Healthcare company based in San Francisco (United States) founded in 2018. An AI-enabled platform is developed for infectious disease treatment. Insitro has raised $643.21 million across 3 funding rounds from investors including Verily, ARE and WuXi AppTec. The company has 257 employees. Insitro has completed 1 acquisition, including Haystack Sciences. Its website insitro.com draws about 28 thousand monthly visits. Insitro offers products and services including insitro Platform and Therapeutic Pipeline. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Insitro was founded in 2018 and is headquartered in San Francisco, United States. An AI-enabled technology platform is utilized by the company to advance drug discovery and development. Focus is placed on infectious diseases such as HIV and hepatitis C, alongside cancer and genetic conditions like cystic fibrosis. Operations center on integrating machine learning with biological data to identify therapeutic targets in the biotechnology sector.
- Headquarters San Francisco, United States
- Employees 257
- SectorsHealthcare
- Website insitro.com
- Social LinkedIn X
- Total Equity Funding$643.21M (USD)
in 3 rounds
- Latest Funding Round$400M (USD), Series C
Mar 2021
- InvestorsVerily
& 16 more
- Employee Count257
- Investments & Acquisitions
Products & Services of Insitro
Insitro offers a comprehensive portfolio of products and services, including insitro Platform and Therapeutic Pipeline.
Integrates data to accelerate drug discovery and development processes
Focuses on metabolism, oncology, and neuroscience for new medicines
Funding Insights of Insitro
Insitro has successfully raised a total of $643.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $400 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $643.21M
- Total Rounds 3
- Last Round Series C — $400M
- First Round $100M
(Jul 2019)
- Investors Count 17
All 3 funding rounds of Insitro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $400M | Series C | – | CPP Investments | |
| Mar 2020 | $143.21M | Series B | – | a16z | |
| Jul 2019 | $100M | Series A | – | Arch Venture Partners, Foresite Capital |
17 investors in total: 17 institutional.
Investors in Insitro
Insitro has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Verily, ARE and WuXi AppTec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
HOF Capital is engaged in venture capital investments. | hofcapital.com | New York, United States |
Investor details for Insitro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Insitro
28 people are tracked at Insitro (14 in leadership, 8 in board & advisors, 6 in team); the tracked headcount is 257.
| Name | Role | Group |
|---|---|---|
Stephen Meadows | Associate Director, Administration | Executive Assistant To The CEO | Leadership |
Sungjin Lee | Director | Leadership |
Ajamete Kaykas | Chief eXploration Officer & Head of Neuroscience | Leadership |
Philip Tagari | Chief Scientific Officer | Leadership |
Eray Watts | VP, High Throughput Chemistry | Leadership |
Daphne Koller | Founder & CEO, Board Member | Leadership |
Mary Rozenman | CFO & CBO | Leadership |
S. Michael Rothenberg | Chief Medical Officer | Leadership |
David Lloyd | VP, Metabolic Disease | Leadership |
Samuel Sances | Director Of Neuroscience | Leadership |
Eva Czirr | Director Biology (neuroscience) | Leadership |
Eddie Ray Watts | Vice President Of High-throughput Chemistry | Leadership |
Monica Woelffer | Director, Financial Reporting & Technical Accounting | Leadership |
Shira Becker | Director, Corporate And Strategic Finance | Leadership |
Roger Perlmutter | Independent Board Director | Board & advisors |
Krishna Yeshwant | Board Observer | Board & advisors |
Vijay Pande | Board Member | Board & advisors |
Paul Mccracken | Board Member | Board & advisors |
Reid Huber | Board Observer | Board & advisors |
Eli Casdin | Board Observer | Board & advisors |
8 more people are available in the full profile.
Complete people profiles for Insitro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insitro
Insitro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Haystack Sciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proprietary platform employed for small molecule drug discovery. | haystacksciences.com | San Francisco, United States | 2016 | Oct 2020 | •••• |
Complete acquisition details for Insitro
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Insitro
4 dated milestones of Insitro across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Insitro is founded.
- Funding First funding round of $100.0M.
- Acquisition Acquires Haystack Sciences.
- Funding Latest funding round, Series C, of $400.0M.
Competitors of Insitro
Insitro has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Insitro
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Insitro
The website of Insitro (insitro.com) receives about 28.4K visits a month.
- Monthly visits28.4K
▲ 39% vs previous month
Websites whose visitors overlap most with Insitro. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biospace.com | 100% | 720.1K | #88,394 | View details | |
| nature.com | 89% | 33.6M | #1,922 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Insitro (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Insitro
Complete news archive for Insitro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insitro
Insitro was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Insitro is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Insitro is a funded company, having raised a total of $643.21M across 3 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Jul 2019.
Insitro has 257 employees.
Insitro was founded in 2018 and is headquartered in San Francisco, United States. An AI-enabled technology platform is utilized by the company to advance drug discovery and development. Focus is placed on infectious diseases such as HIV and hepatitis C, alongside cancer and genetic conditions like cystic fibrosis. Operations center on integrating machine learning with biological data to identify therapeutic targets in the biotechnology sector.
Insitro's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Insitro offers insitro Platform and Therapeutic Pipeline.
Insitro has made 1 acquisition, including Haystack Sciences.
Insitro has 17 investors. Key investors include Verily, ARE, WuXi AppTec, BlackRock, and Mubadala.